The Lupus Foundation of America, in partnership with Eli Lilly and Company and the research firm ICON plc, is conducting an online national research study to better understand the impact of lupus on people with the disease and their caregivers.
The Lupus Foundation of America will partner with the Foundation for the National Institutes of Health (FNIH) to support a new five-year initiative that will accelerate the ability to develop new medicines for lupus and other diverse and complex diseases.
What a way to kick off 2014! Last night, the House and Senate appropriators dropped the Omnibus Appropriations bill.
Northwestern Medicine® scientists have successfully tested a nontoxic therapy that suppresses Lupus in blood samples of people with the autoimmune disease. This is a positive step toward one day developing a vaccine-like therapy that could keep Lupus in remission in the human body without the use of toxic drugs.
There are substantial racial disparities in the burden of lupus, according to initial data from the largest and most far-reaching epidemiology study ever conducted on the disease lupus and published online today by the journal, Arthritis and Rheumatism and in print in a 2014 issue of the journal. New data from two registries, part of the National Lupus Patient Registry (NLPR), also reveal that black females disproportionately are burdened by lupus, a devastating and complicated autoimmune disease.